TCR-Based Therapies for Solid Tumours

On March 22, 2023 Anocca reported that it will attend TCR-Based Therapies for Solid Tumours summit (Press release, Anocca, MAR 22, 2023, View Source [SID1234629150]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Reagan Jarvis, our CEO, is presenting ‘Systematic Isolation & Characterization of Clinical TCR Candidates’ at the TCR-Based Therapies for Solid Tumours, where he discusses native and optimized TCR frameworks, TCR cross-reactivity including insights and practical benchmarks and preventing TCR allo-reactivity.